GLG News by Rituxan Prescribers for NHL: Lymphoma Oncologists (US)
Request a free trial
December 1, 2008
Avastin Raises Risk of Clots: New News?
Analysis of: Scientists recommend 'black box' for Avastin | www.fiercepharma.com
Author: Michael Grossbard, Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons
Avastin Raises Risk of Clots: New News?
Analysis of: Scientists recommend 'black box' for Avastin | www.fiercepharma.com
Author: Michael Grossbard, Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons
In pooled data from 8000 patients across 15 studies, the risk of blood clots was increased by 12% in patients receiving Avastin.
November 10, 2008
Big Pharma will continue to thrive in new administration, but not insurnace companies
Analysis of: Pharma need not worry too much about President Obama | www.pharmatimes.com
Author: GLG Expert Contributor
Analysis of: Pharma need not worry too much about President Obama | www.pharmatimes.com
Author: GLG Expert Contributor
President elect Obama will try , most probably unsuccessfully, to take on insurance companies in orfder to fulfill his election promises of "close to universal" health care.
Generics will thrive, but Big Phrama , especially those with innovative products and biotech companies will continue to pr...
November 10, 2008
Rainfall unlikely to be direct culprit to the Autism Pandemic
Analysis of: Autism linked with rainfall in study | www.boston.com
Author: GLG Expert Contributor
Analysis of: Autism linked with rainfall in study | www.boston.com
Author: GLG Expert Contributor
A recent study infers taht periods of increased rainfall could be linked to increase in number of children dioagnosed with autism.
The causla l;ink of rainfall is unlikely, but most probably reflects other factors like children staying more indoors and thus watch more TV, get less sun exposure and...
November 10, 2008
Avastin for GBM: modest efficacy and soon to be approval
Analysis of: Genentech Submits Application to U.S. Food and Drug Administration for Avastin in the Most Aggressive Form of Brain Cancer | www.gene.com
Author: GLG Expert Contributor
Analysis of: Genentech Submits Application to U.S. Food and Drug Administration for Avastin in the Most Aggressive Form of Brain Cancer | www.gene.com
Author: GLG Expert Contributor
Genetech's Avastin have shown modest increase in progresion free survival and overall survival in patients with gliobalstoma multiforme, the most common and most agressive malignant brain tumor
With such data, Avastin is expected to join Temodar as chemotherapy agent approved for this tumor with...
November 3, 2008
Apidra for Diabetes: No much innovation but will get some use
Analysis of: FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes | www.pipelinereview.com
Author: GLG Expert Contributor
Analysis of: FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes | www.pipelinereview.com
Author: GLG Expert Contributor
Sanofi's rapid acting insulin formulation got FDA approval for use in children 4 years and older with Type I insulin dependent diabetes. The drug has rapid action so it may replace lispro and older short acting insulin preparations, if the price tag is not prohibitive.
October 27, 2008
Nexavar - Vitamin "N" for Solid Tumors???
Analysis of: Phase II Trial of Sorafenib in Advanced Thyroid Cancer | jco.ascopubs.org
Author: GLG Expert Contributor
Analysis of: Phase II Trial of Sorafenib in Advanced Thyroid Cancer | jco.ascopubs.org
Author: GLG Expert Contributor
Two Phase II trials show meanigful prolonged pFS in patients with iodine-refractory thyroid cancer who are treated with Sorafenib ( bayer/Onyx)
The benefit needs to be confirmed in larger trials and need also to establish a favorable safety profile. Studies are needed for combination with other targeted...
October 27, 2008
Immunotherapy for cancer, still have ways to go
Analysis of: Cell Genesys Announces Termination of VITAL-1 Phase 3 Trial of GVAX Immunotherapy for Prostate Cancer | pharmalive.com
Author: GLG Expert Contributor
Analysis of: Cell Genesys Announces Termination of VITAL-1 Phase 3 Trial of GVAX Immunotherapy for Prostate Cancer | pharmalive.com
Author: GLG Expert Contributor
Genesys terminated its studies of its cancer Vaccine for patients with refractory prostate cancer.
Cancer vaccine therapy remains limted to modest advantages in minimal residual diseases and in limted cases of melanoma and NHL
October 27, 2008
Genomics and protemics will be future determinants of "individualized " cancer therapy
Analysis of: Genetic Research May Help Pick Patients' Best Cancer Drugs | online.wsj.com
Author: GLG Expert Contributor
Analysis of: Genetic Research May Help Pick Patients' Best Cancer Drugs | online.wsj.com
Author: GLG Expert Contributor
Genetic testing is the wave of the future to define targets for cancer therapy.
EGFR, K-Ras and FLT-3 testing is just the beginning and affects the use of drugs such as Tarceva ( OSI-Genentech), Erbitux ( Imclone) , Veibitix ( Amgen) and Lasteurinib ( cephalon).
The ultimate goal is to use more sophisticated...
October 27, 2008
K-ras testing will be a reality soon, Bad news for EGFR inhibitors, but good news for Avastin
Analysis of: Targeting EGFR in Colorectal Cancer | content.nejm.org
Author: GLG Expert Contributor
Analysis of: Targeting EGFR in Colorectal Cancer | content.nejm.org
Author: GLG Expert Contributor
K-Ras mutaions analysis in colorectal cancer may become a pre-requiste for use of anti-EGFR antibodies in therapy
Erbitux and Vecitibix use may be relegated to less number of cases. This will benefit Avastin ( Genentech) whose mechanism of action is independent of these mutations
August 29, 2008
Amgen Rewords Label: Less Use of Procrit
Analysis of: Amgen Told to Reword Drug Label | www.nytimes.com
Author: Michael Grossbard, Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons
Amgen Rewords Label: Less Use of Procrit
Analysis of: Amgen Told to Reword Drug Label | www.nytimes.com
Author: Michael Grossbard, Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons
The FDA required Amgen to revise the label for Procrit and Aranesp so that these agents are not used until a patient's hemoglobin drops below 10 or in the setting of potentially curative therapy.
Page : 1 2 3 4 5 6 7 8 9 10 Next1 to 10 of 323
More GLG News in
Healthcare
Most Popular:
Source Article | Expert Analyses
Use of Antipsychotics in Children Is Criticized
www.nytimes.com
Scientists recommend 'black box' for Avastin
www.fiercepharma.com
Are Costly Diabetes Pills Doing Any Good?
www.pharmalot.com
How a Drug Maker Tries to Outwit Generics
online.wsj.com
Use of Antipsychotics in Children Poses Risks of Adverse Effects
November 26, 2008
Avastin and clots? News to me. Black box warning? Why?
November 24, 2008
Off Label Use Can Be Prevented
November 24, 2008
Gardasil will most certainly be approved for boys
November 24, 2008
Medivations's (MDVN) Dimebon - We've Seen This Movie Before
November 24, 2008

